Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.
Elizabeth E Reed, Chief Legal Officer und General Counsel, hat am 15. September 2026 37.500 Aktien von Travere Therapeutics ...
Travere Therapeutics insider Inrig Jula exercised options for 32,395 shares at $8.93 each, followed by the sale of 44,674 ...
Jula Inrig, Executive Vice President, Head of Research & Development & Chief Medical Officer, on September 15, 2026, sold 44,674 shares in Travere Therapeutics (TVTX) for $2,785,021. Following the ...
On September 15, 2026, Travere Therapeutics CFO Cline Christopher R. exercised options for 20,000 shares at an exercise price ...
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...
William E. Rote, Chief Research Officer, hat am 15. September 2026 209.048 Aktien von Travere Therapeutics für 13.135.397 USD verkauft. Nach der Form-4-Meldung bei der SEC kontrolliert ...
9月16日，苏州信诺维医药科技股份有限公司（股票代码：688837）正式登陆上海证券交易所科创板。本次公开发行股票6532.34万股，发行价格27.60元/股，对应发行市盈率59.34倍，募集资金总额18.03亿元。 信诺维上市首日盘中一度暴涨72%，次日继续冲高，盘中最高触及78.98元，较27.60元发行价大涨约186% ；即便冲高回落，收盘55.60元仍较发行价翻倍有余，两日成交异常火爆。
This is my thirteenth Ligand article, following my most recent 06/2026's "Ligand Pharma: Expect Bright And Exciting Future ...
Ligand Pharmaceuticals is rated a Hold, preferring entry after a pullback, given valuation risks and concentration concerns.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Investors.com will undergo scheduled maintenance from 10:00 PM ET to 2:00 AM ET and some features may be unavailable. We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results